Activation of Separase proteolytic activity exclusively in p210BCR-ABL-positive cells during IM treatment may act as a driving force for centrosomal amplification, contributing to genomic instability, clonal evolution and resistance in CML. The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.